Synapse - Works

Results (5608)

Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)

Meeting Abstract

Lee, C. H.; Adachi, Y.; Ikezawa, H.; Li, S. D.; Funahashi, Y.; Minoshima, Y.; Kubiak, P.; Perini, R.; Ren, M.; Smith, A. D.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses

Meeting Abstract

Lee, C. H.; Shah, A. Y.; Hsieh, J. J.; Rao, A.; Pinto, A.; Bilen, M. A.; Cohn, A. L.; Di Simone, C.; Shaffer, D. R.; Girones Sarrio, R.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naive, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)

Meeting Abstract

Msaouel, P.; Siefker-Radtke, A. O.; Sweis, R.; Mao, S.; Rosenberg, J. E.; Vaishampayan, U. N.; Rezazadeh Kalebasty, A.; Pili, R.; Bupathi, M.; Nordquist, L. T.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc)

Meeting Abstract

Madan, R. A.; Slovin, S.; Harshman, L. C.; Wei, X. X.; Bilusic, M.; Karzai, F. H.; Donahue, R. N.; Toney, N. J.; Strauss, J.; Cordes, L.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2

Meeting Abstract

Chowdhury, S.; Patnaik, A.; Campbell, D.; Shapiro, J.; Bryce, A. H.; McDermott, R.; Sautois, B.; Vogelzang, N. J.; Bambury, R.; Voog, E.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Tran, B.; Horvath, L.; Dorff, T.; Rettig, M.; Lolkema, M. P.; Machiels, J. P.; Rottey, S.; Autio, K.; Greil, R.; Adra, N.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations

Meeting Abstract

Schuler, M.; Tabernero, J.; Massard, C.; Vasudeva Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Lu-Emerson, C.; Hargrave, D.; Garcia-Corbacho, J.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Neutrophil-to-lymphocyte ratio as a prognostic factor of disease-free survival in postnephrectomy high-risk locoregional renal cell carcinoma: Analysis of the S-TRAC trial

Journal Article

Patel, A.; Ravaud, A.; Motzer, R. J.; Pantuck, A. J.; Staehler, M.; Escudier, B.; Martini, J. F.; Lechuga, M.; Lin, X.; George, D. J.
Clinical Cancer Research (2020)

Fulltext@MSK | Save

Leveraging systematic functional analysis to benchmark an in silico framework distinguishes driver from passenger MEK mutants in cancer

Journal Article

Hanrahan, A. J.; Sylvester, B. E.; Chang, M. T.; Elzein, A.; Gao, J.; Han, W.; Liu, Y.; Xu, D.; Gao, S. P.; Gorelick, A. N.; more...
Cancer Research (2020)

Fulltext@MSK | Save

RAS/MAPK pathway driver alterations are significantly associated with oncogenic KIT mutations in germ-cell tumors

Journal Article

Mata, D. A.; Yang, S. R.; Ferguson, D. C.; Liu, Y.; Sharma, R.; Benhamida, J. K.; Al-Ahmadie, H. A.; Chakravarty, D.; Solit, D. B.; Tickoo, S. K.; more...
Urology (2020)

Fulltext@MSK | Save